The illustration of protein structure (domains) on the left side, and corresponding exons in the FLT3 gene are displayed on the right side. FMS-like tyrosine kinase 3 (FLT3) mutations represent some ...
In preliminary experiments with mice and lab-grown cells, Johns Hopkins Kimmel Cancer Center scientists have found that a protein-signaling process accelerates the work of the gene most frequently ...
Invivoscribe, a global leader in precision diagnostics, is pleased to announce the successful listings of the LeukoStrat CDx FLT3 Mutation Assay in both the United Kingdom (UK) and Switzerland. The ...
– Expanding clinical experience and safety profile of ziftomenib support its evaluation in combination with approved FLT3 inhibitors in frontline AML – – FLT3 mutations occur in approximately 30% of ...
Preliminary data supports BMF-500’s potential as a transformative therapy for patients with FLT3 mutated relapsed or refractory (R/R) acute leukemia BMF-500 showed a favorable safety and tolerability ...
Data from Phase 3 MORPHO trial selected for press briefing and to be presented as oral session during the 2023 European Hematology Association (EHA) Hybrid Congress Exploratory results demonstrated ...
Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® ...
Biomea Fusion (BMEA) announced preliminary data from the ongoing Phase I COVALENT-103 study evaluating BMF-500, the company’s investigational covalent FLT3 inhibitor developed using the proprietary ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results